Alloimmunity in primate heart recipients with CD154 blockade: Evidence for alternative costimulation mechanisms

Agnes M. Azimzadeh, Steffen Pfeiffer, Guosheng Wu, Carsten Schröder, George L. Zorn, Shahrooz S. Kelishadi, Engin Ozkaynak, Marilyn Kehry, James B. Atkinson, Geraldine G. Miller, Richard N. Pierson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background. CD154 mediates key facets of humoral and cellular immunity to alloantigens, and is tolerogenic to influenza antigens in primates. Barriers to CD154-based tolerance induction for primate cardiac allografts have not previously been defined. Methods. Heterotopic cardiac allograft outcomes in cynomolgus monkeys treated with a CD154 inhibitor, IDEC-131 (n=27), were compared to no treatment (n=4) or cyclosporine A (n=6). Results. CD154 blockade significantly prolonged median allograft survival, from 6.2 (range 6, 7, n=4) days in untreated controls, to 39 (8, 112, n=16) days with intensive monotherapy and 93 (>25, 386; n=3) days with added antithymocyte globulin (ATG), but did not yield tolerance. Alloantibody production was delayed but not prevented by IDEC-131 alone or with ATG, and was exacerbated by infusion of donor bone marrow (n=8). Expression of ICOS was prominent in graft infiltrating lymphocytes, and preceded elaboration of antidonor antibody and vasculopathy. Conclusion. CD154 monotherapy modulates primate cardiac alloimmunity, but does not readily induce tolerance. Targeting alternative costimulation pathways, including ICOS, may facilitate tolerance induction based on CD154 blockade.

Original languageEnglish (US)
Pages (from-to)255-264
Number of pages10
JournalTransplantation
Volume81
Issue number2
DOIs
StatePublished - Jan 1 2006

Fingerprint

Primates
Allografts
Antilymphocyte Serum
Isoantibodies
Macaca fascicularis
Isoantigens
Humoral Immunity
Cellular Immunity
Human Influenza
Cyclosporine
Bone Marrow
Lymphocytes
Transplants
Antigens
Antibodies
monoclonal antibody IDEC131

Keywords

  • Alloantibody
  • Allotransplantation
  • CD40L (CD154)
  • Cardiac allograft vasculopathy
  • Chronic rejection
  • Costimulation
  • Heart transplant
  • ICOS
  • Primate
  • T-cell activation

ASJC Scopus subject areas

  • Transplantation

Cite this

Azimzadeh, A. M., Pfeiffer, S., Wu, G., Schröder, C., Zorn, G. L., Kelishadi, S. S., ... Pierson, R. N. (2006). Alloimmunity in primate heart recipients with CD154 blockade: Evidence for alternative costimulation mechanisms. Transplantation, 81(2), 255-264. https://doi.org/10.1097/01.tp.0000190099.62847.e6

Alloimmunity in primate heart recipients with CD154 blockade : Evidence for alternative costimulation mechanisms. / Azimzadeh, Agnes M.; Pfeiffer, Steffen; Wu, Guosheng; Schröder, Carsten; Zorn, George L.; Kelishadi, Shahrooz S.; Ozkaynak, Engin; Kehry, Marilyn; Atkinson, James B.; Miller, Geraldine G.; Pierson, Richard N.

In: Transplantation, Vol. 81, No. 2, 01.01.2006, p. 255-264.

Research output: Contribution to journalArticle

Azimzadeh, AM, Pfeiffer, S, Wu, G, Schröder, C, Zorn, GL, Kelishadi, SS, Ozkaynak, E, Kehry, M, Atkinson, JB, Miller, GG & Pierson, RN 2006, 'Alloimmunity in primate heart recipients with CD154 blockade: Evidence for alternative costimulation mechanisms', Transplantation, vol. 81, no. 2, pp. 255-264. https://doi.org/10.1097/01.tp.0000190099.62847.e6
Azimzadeh, Agnes M. ; Pfeiffer, Steffen ; Wu, Guosheng ; Schröder, Carsten ; Zorn, George L. ; Kelishadi, Shahrooz S. ; Ozkaynak, Engin ; Kehry, Marilyn ; Atkinson, James B. ; Miller, Geraldine G. ; Pierson, Richard N. / Alloimmunity in primate heart recipients with CD154 blockade : Evidence for alternative costimulation mechanisms. In: Transplantation. 2006 ; Vol. 81, No. 2. pp. 255-264.
@article{7bd59ebaa8aa492d8145852420b9742f,
title = "Alloimmunity in primate heart recipients with CD154 blockade: Evidence for alternative costimulation mechanisms",
abstract = "Background. CD154 mediates key facets of humoral and cellular immunity to alloantigens, and is tolerogenic to influenza antigens in primates. Barriers to CD154-based tolerance induction for primate cardiac allografts have not previously been defined. Methods. Heterotopic cardiac allograft outcomes in cynomolgus monkeys treated with a CD154 inhibitor, IDEC-131 (n=27), were compared to no treatment (n=4) or cyclosporine A (n=6). Results. CD154 blockade significantly prolonged median allograft survival, from 6.2 (range 6, 7, n=4) days in untreated controls, to 39 (8, 112, n=16) days with intensive monotherapy and 93 (>25, 386; n=3) days with added antithymocyte globulin (ATG), but did not yield tolerance. Alloantibody production was delayed but not prevented by IDEC-131 alone or with ATG, and was exacerbated by infusion of donor bone marrow (n=8). Expression of ICOS was prominent in graft infiltrating lymphocytes, and preceded elaboration of antidonor antibody and vasculopathy. Conclusion. CD154 monotherapy modulates primate cardiac alloimmunity, but does not readily induce tolerance. Targeting alternative costimulation pathways, including ICOS, may facilitate tolerance induction based on CD154 blockade.",
keywords = "Alloantibody, Allotransplantation, CD40L (CD154), Cardiac allograft vasculopathy, Chronic rejection, Costimulation, Heart transplant, ICOS, Primate, T-cell activation",
author = "Azimzadeh, {Agnes M.} and Steffen Pfeiffer and Guosheng Wu and Carsten Schr{\"o}der and Zorn, {George L.} and Kelishadi, {Shahrooz S.} and Engin Ozkaynak and Marilyn Kehry and Atkinson, {James B.} and Miller, {Geraldine G.} and Pierson, {Richard N.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1097/01.tp.0000190099.62847.e6",
language = "English (US)",
volume = "81",
pages = "255--264",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Alloimmunity in primate heart recipients with CD154 blockade

T2 - Evidence for alternative costimulation mechanisms

AU - Azimzadeh, Agnes M.

AU - Pfeiffer, Steffen

AU - Wu, Guosheng

AU - Schröder, Carsten

AU - Zorn, George L.

AU - Kelishadi, Shahrooz S.

AU - Ozkaynak, Engin

AU - Kehry, Marilyn

AU - Atkinson, James B.

AU - Miller, Geraldine G.

AU - Pierson, Richard N.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Background. CD154 mediates key facets of humoral and cellular immunity to alloantigens, and is tolerogenic to influenza antigens in primates. Barriers to CD154-based tolerance induction for primate cardiac allografts have not previously been defined. Methods. Heterotopic cardiac allograft outcomes in cynomolgus monkeys treated with a CD154 inhibitor, IDEC-131 (n=27), were compared to no treatment (n=4) or cyclosporine A (n=6). Results. CD154 blockade significantly prolonged median allograft survival, from 6.2 (range 6, 7, n=4) days in untreated controls, to 39 (8, 112, n=16) days with intensive monotherapy and 93 (>25, 386; n=3) days with added antithymocyte globulin (ATG), but did not yield tolerance. Alloantibody production was delayed but not prevented by IDEC-131 alone or with ATG, and was exacerbated by infusion of donor bone marrow (n=8). Expression of ICOS was prominent in graft infiltrating lymphocytes, and preceded elaboration of antidonor antibody and vasculopathy. Conclusion. CD154 monotherapy modulates primate cardiac alloimmunity, but does not readily induce tolerance. Targeting alternative costimulation pathways, including ICOS, may facilitate tolerance induction based on CD154 blockade.

AB - Background. CD154 mediates key facets of humoral and cellular immunity to alloantigens, and is tolerogenic to influenza antigens in primates. Barriers to CD154-based tolerance induction for primate cardiac allografts have not previously been defined. Methods. Heterotopic cardiac allograft outcomes in cynomolgus monkeys treated with a CD154 inhibitor, IDEC-131 (n=27), were compared to no treatment (n=4) or cyclosporine A (n=6). Results. CD154 blockade significantly prolonged median allograft survival, from 6.2 (range 6, 7, n=4) days in untreated controls, to 39 (8, 112, n=16) days with intensive monotherapy and 93 (>25, 386; n=3) days with added antithymocyte globulin (ATG), but did not yield tolerance. Alloantibody production was delayed but not prevented by IDEC-131 alone or with ATG, and was exacerbated by infusion of donor bone marrow (n=8). Expression of ICOS was prominent in graft infiltrating lymphocytes, and preceded elaboration of antidonor antibody and vasculopathy. Conclusion. CD154 monotherapy modulates primate cardiac alloimmunity, but does not readily induce tolerance. Targeting alternative costimulation pathways, including ICOS, may facilitate tolerance induction based on CD154 blockade.

KW - Alloantibody

KW - Allotransplantation

KW - CD40L (CD154)

KW - Cardiac allograft vasculopathy

KW - Chronic rejection

KW - Costimulation

KW - Heart transplant

KW - ICOS

KW - Primate

KW - T-cell activation

UR - http://www.scopus.com/inward/record.url?scp=33644872830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644872830&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000190099.62847.e6

DO - 10.1097/01.tp.0000190099.62847.e6

M3 - Article

C2 - 16436970

AN - SCOPUS:33644872830

VL - 81

SP - 255

EP - 264

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -